CR20220382A - Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática - Google Patents
Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmáticaInfo
- Publication number
- CR20220382A CR20220382A CR20220382A CR20220382A CR20220382A CR 20220382 A CR20220382 A CR 20220382A CR 20220382 A CR20220382 A CR 20220382A CR 20220382 A CR20220382 A CR 20220382A CR 20220382 A CR20220382 A CR 20220382A
- Authority
- CR
- Costa Rica
- Prior art keywords
- plasma kallikrein
- inhibitors
- carboxamide derivatives
- heteroaromatic carboxamide
- heteroaromatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157259 | 2020-02-13 | ||
| PCT/EP2021/053286 WO2021160718A1 (en) | 2020-02-13 | 2021-02-11 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220382A true CR20220382A (es) | 2022-09-16 |
Family
ID=69591572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220382A CR20220382A (es) | 2020-02-13 | 2021-02-11 | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática |
| CR20250167A CR20250167A (es) | 2020-02-13 | 2021-02-11 | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática. solicitud divisional 2022-382 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250167A CR20250167A (es) | 2020-02-13 | 2021-02-11 | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática. solicitud divisional 2022-382 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11760745B2 (https=) |
| EP (1) | EP4103562A1 (https=) |
| JP (3) | JP7230277B2 (https=) |
| KR (1) | KR20220141333A (https=) |
| CN (2) | CN116120287B (https=) |
| AR (2) | AR121341A1 (https=) |
| AU (1) | AU2021218952A1 (https=) |
| BR (1) | BR112022013979A2 (https=) |
| CA (1) | CA3168690A1 (https=) |
| CL (2) | CL2022002101A1 (https=) |
| CO (1) | CO2022011254A2 (https=) |
| CR (2) | CR20220382A (https=) |
| DO (2) | DOP2022000157A (https=) |
| EC (1) | ECSP22062410A (https=) |
| IL (2) | IL320007A (https=) |
| JO (1) | JOP20220186A1 (https=) |
| MX (3) | MX2022009941A (https=) |
| PE (2) | PE20231985A1 (https=) |
| SA (1) | SA522440127B1 (https=) |
| TW (2) | TWI873290B (https=) |
| UA (1) | UA130722C2 (https=) |
| WO (1) | WO2021160718A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839711A (zh) | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2025001956A1 (zh) * | 2023-06-30 | 2025-01-02 | 远森制药（杭州）有限公司 | 杂芳族甲酰胺类化合物及其在医药上的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| DE10207037A1 (de) * | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| DE10230012A1 (de) * | 2002-07-04 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 5,6-Dihydro-4H-imidazo[4,5,1-ij]chinoline,ihre Herstellung und ihre Verwendung als Arzneimittel |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2005089362A (ja) | 2003-09-17 | 2005-04-07 | Sumitomo Chemical Co Ltd | アリールピラゾリン化合物及びその用途 |
| EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | METHODS OF TREATING KALLIKREIN RELATED DISORDERS |
| NZ602266A (en) * | 2010-02-11 | 2014-05-30 | Bristol Myers Squibb Co | Macrocycles as factor xia inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| EP2999697B1 (en) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
| US10981893B2 (en) | 2015-07-01 | 2021-04-20 | Attune Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| EP3368524B1 (en) | 2015-10-27 | 2021-08-18 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| WO2017072020A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| DK3464271T3 (da) | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
| US10501440B2 (en) | 2017-04-21 | 2019-12-10 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| CA3063934A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Kinase inhibitors and uses thereof |
| JP6828191B2 (ja) | 2018-08-16 | 2021-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害剤としての複素芳香族カルボキサミド誘導体 |
| DK4031547T3 (da) | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
-
2021
- 2021-02-09 TW TW110104875A patent/TWI873290B/zh active
- 2021-02-09 TW TW114103224A patent/TW202535863A/zh unknown
- 2021-02-11 MX MX2022009941A patent/MX2022009941A/es unknown
- 2021-02-11 CR CR20220382A patent/CR20220382A/es unknown
- 2021-02-11 CR CR20250167A patent/CR20250167A/es unknown
- 2021-02-11 IL IL320007A patent/IL320007A/en unknown
- 2021-02-11 JO JOP/2022/0186A patent/JOP20220186A1/ar unknown
- 2021-02-11 AU AU2021218952A patent/AU2021218952A1/en active Pending
- 2021-02-11 WO PCT/EP2021/053286 patent/WO2021160718A1/en not_active Ceased
- 2021-02-11 PE PE2023001617A patent/PE20231985A1/es unknown
- 2021-02-11 BR BR112022013979A patent/BR112022013979A2/pt unknown
- 2021-02-11 KR KR1020227031639A patent/KR20220141333A/ko active Pending
- 2021-02-11 JP JP2022514811A patent/JP7230277B2/ja active Active
- 2021-02-11 US US17/173,213 patent/US11760745B2/en active Active
- 2021-02-11 CN CN202310088017.6A patent/CN116120287B/zh active Active
- 2021-02-11 PE PE2022001696A patent/PE20221591A1/es unknown
- 2021-02-11 UA UAA202203240A patent/UA130722C2/uk unknown
- 2021-02-11 IL IL295125A patent/IL295125B2/en unknown
- 2021-02-11 CA CA3168690A patent/CA3168690A1/en active Pending
- 2021-02-11 CN CN202180011395.3A patent/CN115052873A/zh active Pending
- 2021-02-11 EP EP21706489.8A patent/EP4103562A1/en active Pending
- 2021-02-12 AR ARP210100385A patent/AR121341A1/es unknown
-
2022
- 2022-08-03 DO DO2022000157A patent/DOP2022000157A/es unknown
- 2022-08-04 CL CL2022002101A patent/CL2022002101A1/es unknown
- 2022-08-10 EC ECSENADI202262410A patent/ECSP22062410A/es unknown
- 2022-08-10 CO CONC2022/0011254A patent/CO2022011254A2/es unknown
- 2022-08-11 SA SA522440127A patent/SA522440127B1/ar unknown
- 2022-08-12 MX MX2025013435A patent/MX2025013435A/es unknown
- 2022-08-12 MX MX2025013436A patent/MX2025013436A/es unknown
-
2023
- 2023-02-15 JP JP2023021625A patent/JP7703587B2/ja active Active
- 2023-04-28 CL CL2023001244A patent/CL2023001244A1/es unknown
- 2023-08-25 US US18/455,865 patent/US12479827B2/en active Active
- 2023-09-14 DO DO2023000195A patent/DOP2023000195A/es unknown
- 2023-09-18 US US18/468,885 patent/US20240076286A1/en active Pending
- 2023-11-17 AR ARP230103113A patent/AR131110A2/es unknown
-
2025
- 2025-06-25 JP JP2025107413A patent/JP2025148369A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220382A (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| MX380276B (es) | Inhibidor jak. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX382562B (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub). | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MX384624B (es) | Derivados de pirazol como inhibidores de calicreina plasmatica. | |
| EA201891917A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| JOP20240181A1 (ar) | مثبطات هيليكاز الـ rna dhx9 واستخداماتها | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| WO2019195641A3 (en) | 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same | |
| MX2022004713A (es) | Derivados de tiofeno como inhibidores de xantina oxidasa y aplicacion de los mismos. | |
| MX2023015246A (es) | Compuestos pirimidinicos para usar como inhibidores de map4k1. | |
| MX389403B (es) | Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo | |
| WO2023122325A3 (en) | Meta anilide compounds and methods for use of the same to treat diseases and disorders | |
| GEAP202516658A (en) | Ripk1 inhibitors and methods of use |